MITIGATE is a real world study evaluating the clinical effectiveness of pre-treatment with icosapent ethyl (IPE) compared to usual standard of care to prevent and reduce sequelae of laboratory-confirmed upper respiratory tract infection (URI) (COVID-19, influenza etc) in patients with established atherosclerotic cardiovascular disease (ASCVD).
